Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
US Department of Justice
Dow
Teva
AstraZeneca
UBS
Julphar
Chubb

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,214,052

« Back to Dashboard

Summary for Patent: 5,214,052
Title: Method for dissolving arginineamides and pharmaceutical compositions containing them
Abstract:A method for dissolving an arginineamide of the invention comprising dissolving N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I) ##STR1## wherein R.sup.1 represents a (2R, 4R)-4-alkyl-2-carboxypiperizino group and R.sup.2 represents a phenyl group or a condensed polycyclic compound residue which may be substituted with one or more substituents selected from lower alkyl groups, lower alkoxy groups and lower alkyl-substituted amino groups, said condensed polycyclic compound residue including a benzene ring which binds to sulfur atom of the sulfonyl group in the general formula (I) and is condensed with one or more other rings which may be heterocyclic and having 7 to 14 carbon atoms as the ring-constituent atoms; and/or its salt in a solvent of alcohol and water is disclosed herein. And, the pharmaceutical composition comprising N.sup.2 -arylsulfonyl-L-arginineamide having the general formula (I), an alcohol and water is disclosed herein.
Inventor(s): Ofuchi; Kunihiko (Hasaki, JP), Nomura; Tatsuo (Hasaki, JP)
Assignee: Mitsubishi Kasei Corporation (Tokyo, JP)
Application Number:07/851,248
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Drugs Protected by US Patent 5,214,052

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,214,052

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan62-188484Jul 28, 1987

International Patents Family Members for US Patent 5,214,052

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0301970 ➤ Try a Free Trial
Germany 122005000056 ➤ Try a Free Trial
Germany 3866303 ➤ Try a Free Trial
Japan S6431727 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Queensland Health
Cantor Fitzgerald
UBS
Cerilliant
Fuji
Express Scripts
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.